BioProcess International

Regulatory Frameworks for Central Nervous System Safety Assessment: Bridging Traditional Methods and New Modalities

Despite new methodologies and flexible regulatory pathways, CNS biopharmaceuticals still face significant safety assessment ...
TMCnet

insitro to Acquire CombinAbleAI to Complete its Full Stack, Modality-Agnostic AI Platform for Drug Discovery and Design

AI therapeutics company built on causal biology, today announced the acquisition of CombinAbleAI and the launch of insitro's TherML™ (Therapeutic Machine Learning) platform. The acquisition, which is ...
Morningstar

Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities

SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader and more ...
Drug Target Review

insitro expands AI drug discovery with CombinAbleAI acquisition

insitro has acquired Israeli AI therapeutics company CombinAbleAI and launched its TherML platform, creating an end-to-end, modality-agnostic system for designing small molecules, antibodies, ...
EurekAlert!

Nature Communications: Insilico Medicine presents AI-empowered dual-action PROTAC targeting PKMYT1

AI Designs a Novel PROTAC from Scratch: Insilico's generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its ...